Results 171 to 180 of about 283,224 (387)

Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
This review examines the PGx annotations in package inserts (bulas in Brazilian Portuguese) approved by ANVISA, the Brazilian Health Regulatory Agency, for 19 gene–drug pairs with strong or moderate recommendations for initial dosing alteration in the CPIC (Clinical Pharmacogenetic Implementation Consortion) guidelines and PGx testing required or ...
Guilherme Suarez‐Kurtz
wiley   +1 more source

Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Donafenib and Camrelizumab in the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Retrospective, Single-Arm Study

open access: yesJournal of Hepatocellular Carcinoma
Chenrui Wu,1,* Zixuan Fu,1,* Long Pan,1 Jiachu Li,2 Yin Zhou,3 Ruirui Sun,1 Yang Gou,1 Yaowu Zhao,1 Zhouyan Wang,1 Yuhao Qiu,1 Ping Huang1 1Department of Hepatobiliary Surgery, First Affiliated Hospital of Chongqing Medical University ...
Wu C   +10 more
doaj  

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

open access: yesJournal of Clinical Oncology, 2004
R. Goldberg   +8 more
semanticscholar   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

open access: yesBMEMat, EarlyView.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen   +7 more
wiley   +1 more source

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

open access: yesNew England Journal of Medicine, 2000
L. Saltz   +11 more
semanticscholar   +1 more source

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

open access: yesCancer Communications, EarlyView.
Abstract Background Glecirasib, an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine‐to‐cysteine substitution at codon 12 (KRAS G12C), has exhibited clinical activity in non‐small‐cell lung cancer (NSCLC) and colorectal cancer (CRC).
Jian Li   +31 more
wiley   +1 more source

Home - About - Disclaimer - Privacy